Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4147234 | 0.91 | CYP2D6 (0.40) | CYP2D6TSHRSMN1; SMN2KMT2ASLC18A3 | |
| SCHEMBL5950942 | 0.82 | SMN1; SMN2 (0.47) | CYP2D6SMN1; SMN2BDKRB1 | |
| SCHEMBL5950940 | 0.82 | SMN1; SMN2 (0.47) | CYP2D6SMN1; SMN2BDKRB1 | |
| SCHEMBL4133986 | 0.80 | LTA4H (0.44) | CYP2D6KMT2ASLC18A3LTA4HKDM4E | |
| SCHEMBL4149726 | 0.76 | ALDH1A1 (0.50) | TSHRSMN1; SMN2KMT2ALTA4HKDM4E | |
| SCHEMBL3570796 | 0.73 | MAP3K14 (0.41) | BDKRB1 | |
| SCHEMBL3570792 | 0.73 | MAP3K14 (0.41) | BDKRB1 | |
| SCHEMBL4147058 | 0.73 | KMT2A (0.53) | KMT2ALTA4HKDM4EGAA | |
| SCHEMBL4148884 | 0.71 | CYP3A4 (0.41) | CYP2D6MAOAKMT2ALTA4HMAOB | |
| SCHEMBL4141579 | 0.70 | KIF11 (0.36) | MAOBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | CYP2D6 48/4885MAOA 470/4885TSHR 4705/4885 |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | LTC4S, PTGES, LTB4R2 | CYP2D6 48/4885MAOA 470/4885TSHR 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.